Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis

Mostafa Hosseini¹, Amir Almasi-Hashiani², Mahdi Sepidarkish³ and Saman Maroufizadeh⁴*

Abstract

Background: Asthma-COPD overlap (ACO) is a term that encompasses patients with features of both asthma and COPD. To date, the global prevalence of ACO in the general population remains unknown. The objective of this study was to estimate the prevalence of ACO in the general population using a systematic review and meta-analysis.

Methods: A systematic search of ISI Web of Knowledge, MEDLINE/PubMed, and Scopus was performed up to May 2019 to identify studies reporting the prevalence of ACO. Reference lists from identified studies and relevant review articles were also searched. Eligibility criteria were studies reporting the prevalence of ACO, performed in general population, and published in English language. Pooled prevalence of ACO with 95% confidence interval (CI) was calculated using random effects Meta-analysis.

Results: A total of 27 studies were included in this meta-analysis. The Cochran Q test and I² statistics revealed substantial heterogeneity among studies. Based on the random-effects model, the pooled prevalence of ACO was 2.0% (95% CI: 1.4–2.6%) in the general population, 26.5% (95% CI: 19.5–33.6%) among patients with asthma, and 29.6% (95% CI: 19.3–39.9%) among patients with COPD. In addition, for included studies, the global prevalence of asthma-only was 6.2% (95% CI: 5.0–7.4%) and COPD-only was 4.9% (95% CI: 4.3–5.5%).

Conclusion: We estimated the global prevalence of ACO based on population-based studies and found that 2.0% of the general population is affected. However, the prevalence of ACO depends on its diagnostic criteria. Therefore, there is a vital need to better define the ACO diagnostic criteria, management and treatment. It is worth noting that the limitations of the present study include lack of studies in some region of the world and small number of studies included in the subgroup analyses.

Keywords: Asthma, COPD, Asthma-COPD overlap, Prevalence, Meta-Analysis, Systematic Review

Background

Asthma and chronic obstructive pulmonary disease (COPD) are major public health problem and represent a leading cause of morbidity and mortality worldwide [1, 2]. Asthma and COPD are the most common chronic respiratory diseases worldwide each with a unique natural history and pathophysiology [1]. Asthma is usually characterized by chronic airway inflammation whereas COPD is characterized by persistent respiratory symptoms and chronic inflammation of the airways [3, 4]. However, patients can sometimes have clinical features of both diseases, and this condition has been termed asthma-COPD overlap (ACO), recommended by joint GINA (Global Initiative for Asthma) and GOLD (Global Initiative for Chronic Obstructive Lung Disease) guideline. According to this guideline, ACO is characterized by “persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD”. Furthermore, many studies use the term asthma-COPD overlap syndrome (ACOS), but based on the recent change recommended by the GINA and GOLD in 2017, we will use ‘ACO’ as a term for this condition as it is not
considered a single entity but a group of phenotypes [4]. Although asthma and COPD have been well defined, there is currently no consensus on the definition of ACO.

Most previous studies revealed that patients with ACO have more respiratory symptoms, more frequent exacerbations, poor quality of life, higher mortality rate, increased health care utilization, and higher prevalence of comorbidities than those with either asthma or COPD only [5–9].

Numerous population-based studies have been carried out to estimate the prevalence of ACO throughout the world, especially in the USA and Europe [10–36]. However, there is a considerable variation among the studies. The prevalence of ACO has varied widely in these studies from 0.3 to 5.0% in the general population, from 3.2 to 51.4% in patients with asthma, and from 12.6 to 55.7% in patients with COPD. Although there are currently a limited number of population-based studies in this context, it has been growing in recent years.

The global prevalence of ACO remains unknown, and no systematic review and meta-analysis of population-based studies has yet been conducted. On the other hand, due to the considerable heterogeneity among the reported prevalence of ACO, and its significant public health impact, the exact prevalence of ACO is critical for strategic plan and health policy. We therefore conducted a systematic review and meta-analysis of the published literature to examine this parameter. We examined the prevalence both in the general population and among patients with asthma or COPD to understand better the absolute burden of this condition.

Methods

This systematic review adheres to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist [37].

Search strategy

A systematic literature search was performed in ISI Web of Knowledge, MEDLINE/PubMed, and Scopus databases up to 30 May 2019 to identify studies reporting the prevalence of ACO. The search strategy in ISI Web of Knowledge is outlined in detail in Table 1. The other databases were searched with similar terms. Reference lists from identified studies and relevant review articles were also searched for studies eligible for inclusion.

Outcomes

Our primary outcome of interest was prevalence of ACO in the general population. Secondary outcomes included the prevalence of ACO in patients with asthma and patients with COPD, prevalence of asthma-only, and prevalence of COPD-only. Table S1 presents definitions of asthma, COPD, and ACO in included studies.

Inclusion and exclusion criteria

The following inclusion criteria were used to select studies: (1) studies reporting the prevalence of ACO, (2) population-based studies, (3) studies published in English language. No time restriction for publication dates was used. The following articles were excluded: (1) studies with no usable data, (2) repeated or overlapping studies, and (3) reviews, meta-analysis, and case reports articles.

Data extraction and quality assessment

Data were abstracted independently by two authors (SM and AAH), and discrepancies were resolved by consensus. The following study characteristics were extracted: first author’s name, year of publication year, country, region, study name, study period, age, sample size, and prevalence of ACO (point or period prevalence). Study quality was assessed independently by two authors (SM and AAH) utilizing the Joanna Briggs Institute’s critical appraisal checklist for studies reporting prevalence data [38]. This tool includes 9 items each of which is rated as either yes, no, not clear, or not applicable [38].

Statistical analysis

All meta-analyses were performed using the Stata version 13.0 (Stata Corp, College Station, TX, USA). The Cochrane Q test ($P < 0.10$) was considered indicative of significant heterogeneity and the $I^2$ statistic (values of 25, 50, and 75% were considered representing low, medium and high heterogeneity, respectively) were used to assess the heterogeneity between studies [39]. Due to the substantial heterogeneity between studies, pooled

| Set | Query                                                                 | Results    |
|-----|------------------------------------------------------------------------|------------|
| #1  | (epidemiology) OR (incidence) OR (Prevalence) OR (Frequency)          | 3483569    |
| #2  | (“Asthma-chronic obstructive pulmonary disease overlap syndrome”) OR (“Asthma and chronic obstructive pulmonary disease overlap syndrome”) OR (“asthma-COPD overlap syndrome”) OR (“asthma-COPD overlap”) OR (“asthma-COPD”) OR (“ACOS”) OR (“mixed asthma-COPD phenotype”) OR (“Asthma combined with COPD”) OR (“coexistence of asthma and COPD”) OR (“COPD with asthmatic features”) OR (“overlap of asthma-COPD”) | 1692       |
| #3  | (“Pulmonary Disease, Chronic Obstructive”) OR (“Chronic Obstructive Pulmonary Disease”) OR (“COPD”) OR (“asthma”) OR (“asthmatic”) OR (“Asthmatic Patient”) | 237,190    |
| #4  | #1 AND #2 AND #3                                                      | 258        |
prevalence of ACO was calculated using a random-effects model. Potential sources of heterogeneity were explored through meta-regression and subgroup analyses with regard to the study region, year of publication, and study quality. Egger's test and a visual inspection of funnel plots were used to assess the presence of publication bias [40, 41].

Results

Study selection
A flow diagram of the study selection process is presented in Fig. 1. A total of 787 articles were retrieved from the different sources. After removal of duplicates, 402 records remained. By screening titles and abstracts, we identified 47 articles; after the inclusion and exclusion criteria were applied, 27 articles remained.

Study characteristics
The study characteristics of the included studies are summarized in Table 2. In total, we included 27 studies published since 2011, except for one study that published in 1996: twelve from Europe [10, 12, 13, 16, 17, 20, 23, 25, 28–30, 35], nine from the North America (United States and Canada) [11, 15, 18, 21, 26, 27, 32–34], three East Asia (China and Korea) [19, 22, 36], three from the Latin America and 6 low- and middle-income countries and Australia [14, 24, 31]. The majority of the included studies were published after 2015. As presented in Table S2, the risk of bias was low in the majority of the criteria in the included studies.

Prevalence of ACO in the general population
As seen in Fig. 2, the lowest and highest prevalence of ACO in the general population was reported by Walsh et al. in UK (0.3%) [10] and Bui et al. in Australia (5.0%) [24], respectively. The Cochran Q test and I^2 statistics revealed substantial heterogeneity among studies (Q (26) = 88,698.3, P < 0.001; I^2 = 100%). Therefore, random effects model was used for statistical analysis. The pooled prevalence of ACO in the general population was 2.0% (95% CI: 1.4–2.6%) (Table 3). Furthermore, the shape of funnel plots did not reveal any evidence of obvious asymmetry (publication bias) (Fig. 3). Egger’s test also did not reveal any evidence of publication bias (P = 0.576).
Table 2 Description of the studies included in the meta-analysis

| First author | Pub. Year | Country | Region | Study | Study Period | Age Sample Size | Prevalence (%) | ACO Asthma-only | COPD-only | ACO in asthma patients | ACO in COPD Patients |
|--------------|-----------|---------|--------|-------|--------------|----------------|----------------|-----------------|-----------|------------------------|----------------------|
| 1 Walsh LJ   | 1996 UK   | Europe  | NA     | NA    | > 4          | 38,865         | 0.3 8.4 0.8 | 3.2 25.4        |           |                        |                      |
| 2 Diaz-Guzman E | 2011 USA  | North America | NHANES III | 1988–2006 | > 25 | 15,203         | 2.3 4.7 5.4 | 33.5 30.5      |           |                        |                      |
| 3 de Marco R | 2013 Italy | Europe  | GEIRD  | 2007– 84 | > 84 | 8360          | 2.1 6.7 5.2 | 23.8 28.9      |           |                        |                      |
| 4 Miravititles M | 2013 Spain | Europe | EPI-SCAN | 2006–2007 | > 80 | 3802          | 1.8 NA 8.4 | 8.4 NA          |           |                        |                      |
| 5 Menezes AMB | 2014 Latin America | Latin America | PLATINO | 2002–2004 | > 40 | 5044          | 1.8 1.7 11.8 | 51.4 13.0      |           |                        |                      |
| 6 Pleasants RA | 2014 USA  | North America | NC BRFSS | 2007–2009 | > 18 | 24,073        | 3.4 5.2 4.7 | 39.3 41.4      |           |                        |                      |
| 7 Lindström I | 2015 Finland  | Europe  | NA     | 2000–2001 | > 63 | 3406          | 0.7 5.9 2.6 | 11.1 22.3      |           |                        |                      |
| 8 van Boven JF | 2016 Spain  | Europe  | MAJORICA | 2012–2013 | > 18 | 916,843       | 0.6 NA 2.5 | NA 18.3        |           |                        |                      |
| 9 Kumbhare S | 2016 USA  | North America | BRFSS | 2012 > 35 | > 35 | 80,498        | 3.2 5.6 6.0 | 36.6 35.0      |           |                        |                      |
| 10 Ding B | 2016 China | East Asia | China NHWS | 2010–2013 | > 18 | 59,935        | 0.6 1.4 2.7 | 30.7 18.6      |           |                        |                      |
| 11 Bonten TN | 2016 The Netherlands | Europe | NEO | 2008–2012 | > 65 | 5675          | 1.3 NA 2.5 | NA NA          |           |                        |                      |
| 12 Mannino DM | 2017 USA  | North America | NHANES | 2007–2012 | > 79 | 12,964        | 2.2 5.8 8.4 | 27.7 20.8      |           |                        |                      |
| 13 Kim J | 2017 Korea | East Asia | KNHANES IV | 2007–2009 | > 19 | 11,656        | 2.2 5.8 8.4 | 27.7 20.8      |           |                        |                      |
| 14 Ferrante G | 2017 Italy  | Europe  | PASSI  | 2013–2015 | > 69 | 108,705       | 1.0 3.4 2.6 | NA NA          |           |                        |                      |
| 15 Bui DS | 2017 Australia | Australia | TAHS | 2006–2008 | > 45 | 1355          | 5.0 19.9 4.4 | 20.2 53.5      |           |                        |                      |
| 16 Baarnes CB | 2017 Denmark | Europe | DCH | 1993–2013 | > 64 | 57,053        | 1.2 2.1 5.9 | 35.9 16.4      |           |                        |                      |
| 17 Kendzerska T | 2017 Canada | North America | ICES | 2002–2012 | > 35 | 7,589,414    | 3.3 NA NA | NA NA          |           |                        |                      |
| 18 Senthilselvan A | 2018 Canada | North America | CHMS | 2007–2013 | > 30 | 9059          | 1.6 6.6 2.2 | 19.3 41.9      |           |                        |                      |
| 19 Henriksen AH | 2018 Norway | Europe  | HUNT  | 2006–2008 | > 20 | 50,777        | 1.9 9.8 1.5 | 16.2 55.2      |           |                        |                      |
| 20 Ekerljung L | 2018 Sweden | Europe | WSAS | 2008–2012 | > 75 | 1172          | 3.4 NA NA | NA NA          |           |                        |                      |
| 21 Mindus S | 2018 Northern Europe | Europe | GA2LEN and RHINE III | 2008 and 2010–2012 | > 40 | 25,429        | 1.0 6.5 1.4 | 13.1 40.8      |           |                        |                      |
| 22 Morgan BW | 2018 6 low- and middle-income countries | Europe | CRONICAS, PRISA, and LINK | 2010– ... | > 92 | 11,923        | 3.8 13.6 4.8 | 21.7 43.8      |           |                        |                      |
| 23 Mendy A | 2018 USA | North America | NHNES | 2007–2012 | > 40 | 7570          | 1.0 NA NA | 14.6 12.6      |           |                        |                      |
| 24 Kumbhare S | 2018 USA | North America | NHNES III | NA | NA | 4434          | 2.8 2.7 7.7 | 51.2 27.0      |           |                        |                      |
| 25 Koleade A | 2018 Canada | North America | APS | 2012 > 12 | > 12 | 28,410        | 2.7 NA NA | NA NA          |           |                        |                      |
| 26 Guerriero M | 2018 Italy  | Europe  | NA    | 2011–2012 | > 79 | 1236          | 2.1 5.6 9.1 | 27.4 18.8      |           |                        |                      |
Prevalence of asthma-only and COPD-only

For included studies, the global prevalence of asthma-only was 6.2% (95% CI: 5.0–7.4%) and COPD-only was 4.9% (95% CI: 4.3–5.5%).

Prevalence of ACO among patients with asthma or COPD

Prevalence of ACO among patients with asthma or COPD were reported in 19 and 22 studies, respectively. These values showed considerable variability in patients with asthma (ranging from 3.2 to 51.4%) and COPD (ranging from 13.0 to 55.7%). When these were pooled, the prevalence of ACO was 26.5% (95% CI: 19.5–33.6%) in patients with asthma and 29.6% (95% CI: 19.3–39.9%) in patients with COPD (see Figs. 4 and 5).

Subgroup analysis

Potential sources of heterogeneity were explored through subgroup analyses with regard to the study region, year of publication (before 2015 vs after 2015), and study quality (≤7 vs ≥8). According to our results, prevalence of ACO was not related to study region.

Table 2 Description of the studies included in the meta-analysis (Continued)

| First author | Pub. Year | Country | Region | Study Period | Age Sample Size | Prevalence (%) | ACO Asthma-only | COPD-only | ACO in asthma patients | ACO in COPD Patients |
|--------------|-----------|---------|--------|--------------|----------------|----------------|-----------------|-----------|------------------------|---------------------|
| Kang HR     | 2019      | Korea   | East Asia | NHIS–NSC 2003–2011 | > 40, 1,113,656 | 1.4 1.1 55.7 | 26.5% (95% CI: 19.5–33.6%) | 29.6% (95% CI: 19.3–39.9%) |

ACO: Asthma-COPD Overlap; COPD: Chronic Obstructive Pulmonary Disease
NA: Not available

Fig. 2 Forest plot showing prevalence of ACO in the general population. Note. Squares represent study-specific prevalence estimates (size of the square denotes the study-specific statistical weight); Horizontal lines represent 95% confidence intervals (CIs); Diamond represents summary estimate of Prevalence with corresponding 95% CI.
Discussion
ACO is a newly identified condition with apparently high prevalence, and evidently variable features, which is associated with a high burden of disease. Patients with ACO may have worse outcomes than those with either asthma- or COPD-only. Despite its high prevalence, few population-based studies have examined the prevalence of ACO, and as a result, the epidemiology of this condition remains poorly defined. Furthermore, until 2010 only one study has examined the prevalence of ACO in the population-based studies. Here we present a comprehensive overview of the prevalence of ACO in the general population as well as in patients with asthma-only and COPD-only. The overall prevalence of ACO in the general population was 2.0%. Heterogeneity was observed between included studies. This heterogeneity may be explained by differences in the definitions, diagnostic criteria, disease ascertainment methods, geographic region, population characteristics (e.g., age and smoking), study design, and inherent biases associated with observational studies.

Subgroup analysis was performed to assess ACO prevalence in different geographic regions. Most of the studies originated from either North America or Europe, but others came from Latin America, China, Korea, and six low- and middle-income countries. When stratification was performed by geographic region, no differences in ACO prevalence were found. Data were lacking for regions of Africa and Middle East, and Eastern Europe, so we could not examine the prevalence of ACO in these areas. Because data were lacking for regions of Africa and Middle East, and Eastern Europe, ACO estimates in this meta-analysis may overestimate or underestimate

Table 3 Summary of meta-analysis results

| Outcomes                  | NO. of studies | Pooled estimates | Prevalence (95% CI) | Model | Chi square | P       | I square |
|---------------------------|----------------|------------------|---------------------|-------|------------|---------|----------|
| ACO                       | 27             |                  | 2.0% (1.4–2.6)     | Random| 88,698.3   | < 0.001 | 100%     |
| Asthma-only               | 19             |                  | 6.2% (5.0–7.4)     | Random| 9163.5     | < 0.001 | 99.8%    |
| COPD-only                 | 22             |                  | 4.9% (4.3–5.5)     | Random| 15,367.2   | < 0.001 | 99.9%    |
| ACO in asthma patients    | 19             |                  | 26.5% (19.5–33.6)  | Random| 17,000,000 | < 0.001 | 100%     |
| ACO in COPD patients      | 22             |                  | 29.6% (19.3–39.9)  | Random| 280,000,000| < 0.001 | 100%     |

ACO: Asthma-COPD Overlap, COPD: Chronic Obstructive Pulmonary Disease, CI: Confidence Interval
the global health burden. Thus, future population-based studies are required to estimate and compare the prevalence of ACO in the different geographic regions. Ideally, we would have investigated whether the year of study contributed significantly to the heterogeneity observed between included studies; however, the considerable overlap of the time periods prevented this analysis. Because of this limitation, we alternatively replace year of study with year of publication and found that ACO prevalence were not changed by year of publication.

Of included studies, only one study reported temporal trend of ACO prevalence, which indicated increasing prevalence in time [26]; however, additional population-based studies are necessary to confirm this finding. This upward trend may be explained by increasing prevalence of both asthma and COPD, and improvement in monitoring of patients. To date, only three studies from Canada, Denmark, and Taiwan examined the incidence of ACO in the general population, emphasizing that such data are missing in the literature. In these studies, the incidence per 1000 person-years was as follows: Canada, 2.1 [26]; Denmark, 0.64 [25]; and Taiwan, 0.70 [42].

The prevalence of ACO among patients with COPD ranged from 12.6 to 55.7% with pooled prevalence of 29.6%. This finding is consistent with a recent meta-analysis, in which the ACO prevalence among patients with COPD in population-based studies was estimated to be 27.0% [8]. In our study, the prevalence of ACO among patients with asthma ranged from 3.2 to 51.4% with pooled prevalence of 26.5%. In previous studies, the prevalence of ACO among patients with asthma also has varied widely from 11.8 to 27.4% [43–47].

For included studies in this review, the global prevalence of asthma-only was 6.2% and COPD-only was 4.9%. In a recent meta-analysis, the global prevalence of COPD based on the GOLD definition was found to be 12.2% [48]. This difference may be due to the different diagnostic criteria and/or including high-risk population in the analysis. According to Global Burden of Disease Study 2015, asthma and COPD were the most prevalent chronic respiratory disease, affecting 358 and 174 million
Fig. 5 Forest plot showing prevalence of ACO in patients with COPD. Note. Squares represent study-specific prevalence estimates (size of the square denotes the study-specific statistical weight); Horizontal lines represent 95% confidence intervals (CIs); Diamond represents summary estimate of Prevalence with corresponding 95% CI.

Table 4 Summary of meta-regression and subgroup analysis for prevalence of ACO in the general population

| Region of study | NO. of studies | Prevalence of ACO (95% CI) | I-square | Meta-Regression P-Value |
|-----------------|----------------|---------------------------|----------|------------------------|
| Europe          | 12             | 1.3% (1.0–1.6)            | 99.1%    | 0.994                  |
| North America   | 9              | 2.5% (1.9–3.0)            | 99.1%    |                        |
| East Asia       | 3              | 1.4% (0.7–2.0)            | 99.7%    |                        |
| Year of publication ≤ 2015 | 7              | 1.8% (0.7–2.8)            | 99.4%    | 0.995                  |
| > 2015          | 20             | 2.1% (1.4–2.8)            | 100.0%   |                        |
| Study quality   |                |                           |          | 0.865                  |
| Low and Moderate (< 8) | 5              | 2.1% (0.7–3.4)            | 99.5%    |                        |
| High (≥8)       | 22             | 2.0% (1.3–2.6)            | 100.0%   |                        |

ACO Asthma-COPD Overlap, COPD Chronic Obstructive Pulmonary Disease, CI Confidence Interval
people in 2015, respectively. Moreover, COPD and asthma caused 2.6 and 1.1% of global DALYs, respectively [49]. As a large proportion of patients with asthma and COPD have ACO, as well as a worse condition of ACO than asthma- and COPD-only, it is crucial to increase the awareness of ACO and provide clear management and treatment to reduce the disease burden.

This study has several limitations that should be taken into account when interpreting the results. First, there were no data on ACO prevalence for large regions such as Africa and the Middle East, and Eastern Europe, thus the generalizability of the results may be limited. Further population-based studies, particularly in Asia and Africa, are required to better estimate the global prevalence and incidence of ACO. Second, regarding the issue that values of ACO prevalence depends on diagnostic methods, we could not perform subgroup analysis for this source of between-study heterogeneity. Third, the quality of the included studies was not optimal. Fourth, the number of studies included in the subgroup analyses was relatively small, so the prevalence of ACO in these subgroups may not be accurately represented. Fifth, although our search was comprehensive, we did not search some other database such as Embase, CINAHL and DOAJ, and include non-English language publications and non-published studies.

Conclusion
This study showed that 2.0% of the general population is affected by ACO. This finding indicates the considerable clinical impact and major burden posed by ACO. Given that there is no consensus on ACO definition in the literature, and the dependence of its prevalence on diagnostic method, it is important to provide clear diagnostic criteria, management and treatment for this condition.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12931-019-1198-4.

Additional file 1: Table S1. Definitions of asthma, COPD, and ACO in included studies. Table S2. Quality assessment of included studies in the meta-analysis using Joanna Briggs Institute’s Critical appraisal checklist for studies reporting prevalence data.

Abbreviations
ACO: Asthma-COPD overlap; ACOS: Asthma-COPD overlap syndrome; CI: Confidence Interval; COPD: Chronic obstructive pulmonary disease; GINA: Global Initiative for Asthma; GOLD: Global Initiative for Chronic Obstructive Lung Disease; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Acknowledgements
Not applicable.

Authors’ contributions
SM: Study concept and design; Collection of data; Analysis and interpretation of the data; Drafting of the article. MH: Study concept and design; Collection of data; Analysis of the data; Drafting of the article. MS: Conception and design; Interpretation of the data; Drafting of the article. All authors approved the final version of the manuscript for submission.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 2Department of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran. 3Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran. 4School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran.

Received: 15 August 2019 Accepted: 24 September 2019
Published online: 23 October 2019

References
1. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdellah A. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–858.
2. Ehteshami-Afshar S, Fitzgerald J, Doyle-Waters M, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20(1):11–23.
3. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Berkwitz E, Celli BR, Chen R, Decramer M, Fabbri LM. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. 2017 Report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(S):557–82.
4. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2017. In: www.ginasthma.org. 2017.
5. Andersén H, Lampela P, Nevanlinna A, Säynäjäkangas O, Keitstein T. High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J. 2013;7(4):342–6.
6. Nielsen M, Børres CB, Ulrik CS. Clinical characteristics of the asthma–COPD overlap syndrome—a systematic review. Int J Chron Obstruct Pulmon Dis. 2015;10:1443–54.
7. Boulet LP, Hanania NA. The many faces of asthma-chronic obstructive pulmonary disease overlap. Curr Opin Pulm Med. 2019;25(1):1–10.
8. Alshabanat A, Zafari Z, Albanyan O, Dairi M, Fitzgerald J. Asthma and COPD overlap syndrome (ACOS): a systematic review and meta-analysis. PLoS One. 2015;10(9):e0136065.
9. Wurst KE, Rheault TR, Edwards L, Tal-Singer R, Agusti A, Vestbo J. A comparison of COPD patients with and without ACOS in the ECLIPSE study. Eur Respir J. 2016;47(5):557–62.
10. Walsh L, Wong C, C S, Guhan a, Pringle M, Tattersfield A: The prevalence of diagnosed asthma and COPD in a community population in Nottinghamshire Thorax. 1996, 51A26.
11. Diaz-Guzman E, Khozami M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the US population. COPD. 2011;8(6):400–7.
12. De Marco R, Perse G, Marcon A, Accordini S, Antonucci L, Bugiani M, Casali L, Ferrari M, Nicolini G, Panic M: The coexistence of asthma and chronic obstructive pulmonary disease (COED): prevalence and risk factors in young, etc.
middle-aged and elderly people from the general population. PLoS One. 2013;8(5):e62985.

13. Miravitlles M, Soriano JB, Ancocchea J, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Garcia-Rio F. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013;107(7):1053–60.

14. Menezes AMB, de Oca MM, Perez-Padilla R, Nadeau G, Wehmeier FC, Lopez-Varela MV, Muñoz A, Jardim JR, Jurbinala G, Tálmalo C. Increased risk of exacerbation and hospitalisation in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297–304.

15. Pleasants RA, Ojah JR, Croft JB, Liu Y, Kraft M, Mannino DM, Donohoe JF, Herrick HL. Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD. 2014;11(3):256–66.

16. Lindström I, Luukkonen R, Vasankari T, Kanervisto M, Heliovaara M, Kainu A, Pallasaaho P. Asthma, COPD and the risk of disability pension-11 year register-based follow-up study. Eur Respir J. 2015;46(PA356).

17. van Boven JF, Román-Rodríguez M, Palmer JF, Toledo-Pons N, Cosío BG, Soriano JB. Comorbiditome, pattern, and impact of asthma-COPD overlap syndrome in real life. Chest. 2016;149(1):101–20.

18. Kumbhare S, Pleasants R, Ojah JA, Strange C. Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Ann Am Thorac Soc. 2016;13(6):803–10.

19. Ding B, Dibonaventura M, Karlsson N, Ling X. Asthma-chronic obstructive pulmonary disease overlap syndrome in the urban Chinese population: prevalence and disease burden using the 2010, 2012, and 2013 China National Health and wellness surveys. Int J Chron Obstruct Pulmon Dis. 2016;11:1399–1510.

20. Bonten TN, Kasteleyn MJ, de Mutsert R, Hiemstra PS, Rosendaal FR, Kangaanranta H. Differences between asthma-COPD overlap syndrome: a population-based study. Eur Respir J. 2017;49(5):1602008.

21. Mannino DM, Gan WQ, Wurst K, Davis KJ. Asthma and chronic obstructive pulmonary disease overlap: the effect of definitions on measures of burden. Chronic Obstr Pulm Dis. 2017;4(2):87–96.

22. Kim J, Kim YS, Kim K, Oh Y-M, Yoo KH, Rhee CK, Lee JH. Socioeconomic impact of asthma, chronic obstructive pulmonary disease and asthma-COPD overlap syndrome. J Thorac Dis. 2017;9(6):1547.

23. Ferrante G, Baldissera S, Campostrini S. Epidemiology of chronic respiratory disease and associated factors in the adult Italian population. Eur J Pub Health. 2017;27(6):1110–6.

24. Bui DS, Burgess JA, Lowe AJ, Perret JL, Lodge CL, Bui M, Morrison S, Thompson BR, Thomas PS, Giles GG. Childhood lung function predicts adult chronic obstructive pulmonary disease and asthma-chronic obstructive pulmonary disease overlap disease. Am J Respir Crit Care Med. 2017;196(1):39–46.

25. Baarres CB, Andersen ZJ, Tjanneland A, Ulrik CS. Incidence and long-term outcome of severe asthma-COPD overlap compared to asthma and COPD alone: a 35-year prospective study of 57,053 middle-aged adults. Int J Chron Obstruct Pulmon Dis. 2017;12:547–9.

26. Kendzerska T, Sadatsafavi M, Aaron SD, To TM, Lougheed MD, Bonten TN. Concurrent physician-diagnosed asthma and chronic obstructive pulmonary disease overlap syndrome: a population-based study. Eur Respir J. 2017;49(5):1602383.

27. Senthivelvan A, Beach J. Characteristics of asthma and COPD overlap syndrome (ACOS) in the Canadian population. J Asthma. 2018;1–9.

28. Henriksson AH, Langhammer A, Steinshamn S, Mai X-M, Brumpton BM. The prevalence and symptom profile of asthma–COPD overlap: the HUNT study. COPD. 2018;15(1):27–35.

29. Ekerljung L, Mincheva R, Varghese MJ, Siddharthan T, Chowdhury M, Robinsmith E, Grimm CB, Thomas ED. Prevalence, clinical characteristics and morbidity of the asthma-COPD overlap in a general population sample. J Asthma. 2018;55(5):461–9.

30. Minudes S, Malinovschi A, Ekerljung L, Forbrig B, Giladov T, Jogi R, Franklin KA, Holm M, Johansson A, Middelvedel R, Asthma and COPD overlap (ACO) is related to a high burden of sleep disturbance and respiratory symptoms: results from the RHINE and Swedish GA2LEN surveys. PLoS One. 2018;13(4):e0191555.

31. Morgan BW, Grigsby MR, Siddharthan T, Chowdhury M, Robinsmith E, Grimm CB, Isakpa MM, Miranda J, Bernabe-Ortiz A, Alm D. Epidemiology of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. J Allergy Clin Immunol. 2019;143(4):1598–606.

32. Mandy A, Forno E, Nylonsenga T, Carnahan R, Gasana J. Prevalence and features of asthma-COPD overlap in the United States 2007–2012. Clin Respir J. 2018;12(8):2369–77.

33. Kumbhare S, Strange C. Mortality in asthma-chronic obstructive pulmonary disease overlap in the United States. South Med J. 2018;111(5):293–8.

34. Koleaede A, Farrell J, Murgford G, Gao Z. Prevalence and risk factors of ACO (asthma-COPD overlap) in aboriginal people. J Environ Public Health. 2018;2018:4657420.

35. Guerriero M, Caminati M, Viaggi G, Sennia G, Pomati C. Prevalence and features of asthma-chronic obstructive pulmonary disease overlap in northern Italy general population. J Asthma. 2019;56(1):27–33.

36. Kang H-R, Hong S-H, Ha S-Y, Kim T-B, Lee E-K. Differences in the risk of mood disorders in patients with asthma-COPD overlap and in patients with COPD alone: a nationwide-population-based retrospective cohort study in Korea. Respir Res. 2019;20(1):80.

37. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

38. Munn Z, Moola S, Liy K, Rittano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147–53.

39. Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1593–58.

40. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;1088–101.

41. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected graphically. Am J Epidemiol. 1997;135(10):767–76.

42. Shantakumar S, Pwu R-F, D’Souza L, Wurst K, Kuo Y-W, Yang Y-Y, Gwan Y-C, Chan KA. Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study. BMC Pulm Med. 2018;18(1):16.

43. Sevimli N, Yapar D, Türkhat. The prevalence of asthma-COPD overlap (ACO) among patients with asthma. Turk Thorac J. 2019;20(2):97–102.

44. Kiljander T, Heini T, Venho K, Jaakola A, Lehłamkiä L. Prevalence of asthma–COPD overlap syndrome among primary care asthmatics with a smoking history: a cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15047.

45. Tommola M, Ilmarinen P, Tuomisto LE, Lehtimäki L, Haapaniö P, Niemöli E, Kankaananta H. Differences between asthma–COPD overlap syndrome and adult-onset asthma. Eur Respir J. 2017;49(5):1602383.

46. Harada T, Yamaseki A, Fukushima T, Hashimoto K, Takata K, Kodani M, Okazaki R, Takeda K, Watanabe M, Kuri J. Causes of death in patients with asthma and asthma–chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulm Dis. 2015;10:595–602.

47. Watanabe M, Nomura H, Kuri J, Sano H, Ueda Y, Mikami M, Yamamoto H, Tokuyasu H, Kato K, Konishi T. Differences in the effects of asian dust on pulmonary function between adult patients with asthma and those with asthma–chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulm Dis. 2016;11:183–90.

48. Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. East Mediterr Health J. 2019;25(1):147–57.

49. Soriano JB, Abajojar AA, Abate KH, Abena SF, Agrawal A, Ahmed MB, Aichour AN, Aichour L, Aichour MTE, Alain K. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5(9):691–706.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.